Results 1 to 10 of about 3,523 (219)

Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis [PDF]

Experimental Hematology & Oncology
Letermovir is an antiviral agent that significantly decreases the frequency of cytomegalovirus (CMV) infections following allogeneic hematopoietic stem cell transplantation (allo-HCT); however, its impact on Epstein-Barr virus (EBV) infection remains ...
Jingtao Huang, Jing Zhou, Shixuan Zhang, Ruoxuan Zhang, Zengkai Pan, Luxiang Wang, Chuanhe Jiang, Jiayu Huang, Zilu Zhang, Yanmin Zhao, Yang Cao, Xiaoxia Hu   +11 more
doaj   +4 more sources

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication [PDF]

, 2023
Introduction. Letermovir (LMV) is used for prophylaxis of cytomegalovirus (CMV) reactivation and end-organ disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients (allo-HSCT).
Aguilar, Cristóbal, Albert, Eliseo, Giménez, Estela, Gozalbo Rovira, Roberto Vicente, Guerreiro, Manuel, Navarro Ortega, David, Piñana, José Luis, Solano Vercet, Carlos   +7 more
core   +3 more sources

Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study [PDF]

Frontiers in Cellular and Infection Microbiology
ObjectivesTo compare the efficacy and safety of letermovir and ganciclovir for cytomegalovirus (CMV) prophylaxis in adolescent patients (aged 14-17 years) undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT).MethodsThis observational ...
Ziwei Xu, Xuan Lu, Huafang Wang
doaj   +2 more sources

Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus

Infection and Drug Resistance, 2015
Dante P Melendez,1,2 Raymund R Razonable1,2 1Division of Infectious Diseases, 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA Abstract: Infection with cytomegalovirus is prevalent in ...
Melendez DP, Razonable RR
doaj   +3 more sources

Real-life experience in two cases of secondary prophylaxis with letermovir for CMV infection in solid organ transplantation

Microbiology Spectrum, 2023
The use of valganciclovir as secondary prophylaxis for cytomegalovirus (CMV) infection in solid organ transplantation (SOT) is the most prevalent therapeutic choice, but it has been dismissed by the presence of resistance and toxicity.
Ana-Belén Pérez, Marta Santos Bravo, Elisa Vidal-Verdú, Aurora Páez-Vega, José-Manuel Vaquero-Barrios, José-Luis Montero, María-Ángeles Marcos, Julián Torre-Cisneros   +7 more
doaj   +2 more sources

ID222 Análise de custo-efetividade e impacto orçamentário do letermovir como profilaxia da infecção e doença por citomegalovírus em pacientes adultos soropositivos (CMV R+) receptores de transplante de células-tronco hematopoiéticas alogênico, na perspectiva do Sistema Único de Saúde

Jornal de Assistência Farmacêutica e Farmacoeconomia
Introdução A população de pacientes submetidos ao transplante de células tronco hematopoiéticas (TCTH) é mais suscetível a infecções, devido ao estado imunocomprometido.
Álex Brunno do Nascimento Martins, Bárbara Rodrigues Alvernaz dos Santos, Eduardo Henrique Ferreira Bambirra, Francisco de Assis Acurcio, Luana Oliveira Prata, Juliana Alvares-Teodoro, Maiara Silva Araújo, Roberto Lúcio Muniz Júnior, Wallace Breno Barbosa, Augusto Afonso Guerra Júnior   +9 more
doaj   +3 more sources

Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients [PDF]

Drug Design, Development and Therapy
Yongbing Zhu,* Li Wang,* Yu Xiang, Yaqin Wang, Ai Zhang, Yao Wang, Mengmeng Yin, Jianxin Dun, Yuting Xu, Qun Hu, Wen Yu,* Aiguo Liu* Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University ...
Zhu Y, Wang L, Xiang Y, Wang Y, Zhang A, Wang Y, Yin M, Dun J, Xu Y, Hu Q, Yu W, Liu A   +11 more
doaj   +2 more sources

Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy [PDF]

Hemorrhagic cystitis (HC) is a highly impacting complication in allogeneic hematopoietic stem cell transplantation (HSCT), occurring in 12%–37% of patients. The impact of transplant- and patient-specific variables has been described, with a possible role
Bacigalupo, A., Chiusolo, P., Galli, E., Gandi, C., Mattozzi, A., Metafuni, E., Santangelo, R., Sica, S., Sora', F.   +8 more
core   +3 more sources

Evaluating valaciclovir, letermovir, and maribavir safety in first-trimester human placental development [PDF]

Scientific Reports
Congenital cytomegalovirus (CMV) infection is the leading preventable cause of childhood disability, including sensorineural hearing loss and cerebral palsy in high-income countries.
Ishara Atukorala, Natasha de Alwis, Sally Beard, Swetha Raghavan, Natalie J. Hannan, Lisa Hui   +5 more
doaj   +2 more sources

Revisiting cytomegalovirus in pediatric allogeneic hematopoietic stem cell transplant recipients: current strategies for prevention and management in the letermovir era [PDF]

Frontiers in Pediatrics
CMV infection remains the most common clinically significant infection in pediatric allogeneic hematopoietic stem cell (HCT) recipients, with seropositive recipients of transplants from seronegative donors at the highest risk for complications. In recent
Lisa Hiskey, Diego R. Hijano, Diego R. Hijano, Ramia Zakhour   +3 more
doaj   +2 more sources